IND Sponsors Should Not Contact FDA Reviewers Directly, Draft Guidance Asserts
This article was originally published in The Pink Sheet Daily
Executive Summary
Industry has pressed for more latitude on communications with agency, but FDA emphasizes that review division regulatory project managers should be primary contact.
You may also be interested in...
US FDA To Sponsors: Tell Us More About Your Drug Development Before We Meet
Requests for meetings with FDA staff about products in development should include pertinent details about pediatric study plans, human factors engineering plans and combination product information; new guidance documents on formal meetings under PDUFA VI and communications with IND sponsors operationalize user fee program commitments and will promote earlier, more thorough engagement, agency says.
PDUFA VI: BIO Survey Finds FDA Communication Problems
Data may help industry stake out its negotiating position as formal talks near for user fee reauthorization.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.